CHEK1 and neuroblastoma: Taken together, our results suggest that cytoplasmic localization does not serve as a reliable indicator for the likelihood that p53-wildtype neuroblastomas would be effectively treated with a therapeutic combination of a DNA damaging agent and a Chk1 inhibitor, but the oligomerization status may.